Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. eInterview with
Andrew Weickhardt, MBBS, DMedSc, FRACP What are the main findings of the study?

Dr. Weickhardt: The study was hoping to confirm our earlier published observation that crizotinib use led to low testosterone in male patients. The earlier study was based on our observation of symptoms of low testosterone in some patients treated with the drug, and had suggested strongly that crizotinib led to rapid decrease in testosterone levels, however this was based only on a single center’s patients, and only 19 patients. We hoped to do this by surveying a larger population of crizotinib treated patients across multiple institutions. We serially measured several relevant hormones.
Continue reading